Quince Therapeutics (QNCX) Revenue & Revenue Breakdown
Quince Therapeutics Revenue Highlights
00
Quince Therapeutics Revenue by Period
Quince Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Quince Therapeutics generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Quince Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $168.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $36.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Quince Therapeutics generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Quince Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CAMP | CAMP4 Therapeutics | $186.23M | $795.00K |
| DTIL | Precision BioSciences | $68.70M | $13.00K |
| MGX | Metagenomi | $44.76M | $8.66M |
| CNTB | Connect Biopharma | $26.03M | $48.00K |
| ADVM | Adverum Bio | $1.00M | - |
| ATYR | aTyr Pharma | $353.00K | $190.00K |
| GUTS | Fractyl Health | $120.00K | - |
| IFRX | InflaRx | $61.80K | $36.25K |
| ALXO | ALX Oncology | - | - |
| QNCX | Quince Therapeutics | - | - |
| KLRS | Kalaris Therapeutics | - | - |